Few preliminary studies showed promising antitumor effects of mTOR inhibitors, such as everolimus, in MTC (Druce et al., 2012; Faggiano et al., 2012; Heilmann et al., 2016; Lim et al., 2013). This evidence concerns the gene MTOR and medullary thyroid gland carcinoma.